What's unique about the new Tyk2 inhibitor, deucravacitinib, under study in #PSO and #PsA. #RNL2022 https://t.co/J04uJxeX2v
Links:
Mar-20-2022
Search for Terms or Answers
Search for Terms or Answers
Links:
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
